Clinical bottom line
Proteasome inhibitors (PIs) remain a cornerstone in the management of relapsed/refractory multiple myeloma (RRMM), with recent advances focusing on novel agents, combination regimens, and improved safety profiles. Real-world data confirm their continued efficacy across diverse patient populations, including those with aggressive disease. However, toxicity management, including tumor lysis syndrome risk, requires vigilance. Emerging PI-based triplet and quadruplet therapies, often combined with immunomodulatory drugs and monoclonal antibodies, are shaping current standards of care and improving outcomes in RRMM (Mateos et al., 2022; Chen et al., 2024; Leleu et al., 2019).
What the evidence shows
Mateos et al. (2022) report from the prospective multinational LocoMMotion study that PI-based regimens remain widely used in real-life RRMM treatment, demonstrating meaningful response rates and manageable toxicity in heavily pretreated patients. This study highlights the heterogeneity of current practice and the importance of individualized therapy.
Chen et al. (2024) provide a comprehensive review of therapeutic progress in RRMM, emphasizing next-generation PIs such as carfilzomib and ixazomib, which offer improved potency and oral administration options, respectively. Combination regimens incorporating PIs with immunomodulatory agents and monoclonal antibodies yield superior efficacy.
Leleu et al. (2019) discuss the evolving role of PIs, noting that triplet regimens combining PIs with lenalidomide and dexamethasone have become standard, with ongoing trials exploring quadruplet combinations to deepen responses.
Alsouqi et al. (2021) describe the KD-PACE salvage regimen, which includes a PI backbone, for aggressive RRMM and plasma cell leukemia, demonstrating feasibility and activity in refractory cases.
Suzuki et al. (2018) alert clinicians to the risk of tumor lysis syndrome (TLS) associated with PIs, underscoring the need for prophylaxis and monitoring, particularly in high tumor burden patients.
Richter et al. (2020) and Fuchs et al. (2021) discuss selinexor, a nuclear export inhibitor used in heavily pretreated RRMM including PI-refractory cases, highlighting its role as an adjunct rather than a PI replacement.
Ma et al. (2017) review the safety and efficacy of single, doublet, and triplet PI-based strategies, supporting the trend toward combination therapies to improve outcomes while balancing toxicity.
Caveats and uncertainty
Despite advances, RRMM remains incurable, and resistance to PIs develops over time.
Toxicities such as peripheral neuropathy, cardiovascular events, and TLS require careful management.
Real-world data reveal variability in treatment access and adherence.
Long-term survival benefits of newer PI combinations need further validation.
Optimal sequencing of PIs with emerging agents is not fully established.
How this may change practice
Clinicians should consider incorporating next-generation PIs and combination regimens early in RRMM management to maximize response depth.
Monitoring for TLS and other PI-related toxicities is critical, especially in high-risk patients.
Oral PIs like ixazomib may improve patient convenience and adherence.
Integration of PIs with novel agents such as monoclonal antibodies and nuclear export inhibitors can address refractory disease.
Personalized treatment plans based on patient comorbidities, prior therapies, and disease characteristics will optimize outcomes.
Ongoing clinical trials and real-world studies will continue to inform best practices.